Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing

METHODS: Fifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 µg/h) for five consecutive weeks, starting two weeks prior to the surgery. Simultaneous plasma and cerebrospinal fluid (CSF) samples were collected during spinal anesthes...

Descripción completa

Detalles Bibliográficos
Autores principales: Härkänen, Lasse, Hakomäki, Henriikka, Huopio, Jukka, Kokki, Hannu, Korhonen, Sanni, Lehtonen, Marko, Sjövall, Sari, Kokki, Merja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663223/
https://www.ncbi.nlm.nih.gov/pubmed/37864723
http://dx.doi.org/10.1007/s00228-023-03583-4
_version_ 1785138350986887168
author Härkänen, Lasse
Hakomäki, Henriikka
Huopio, Jukka
Kokki, Hannu
Korhonen, Sanni
Lehtonen, Marko
Sjövall, Sari
Kokki, Merja
author_facet Härkänen, Lasse
Hakomäki, Henriikka
Huopio, Jukka
Kokki, Hannu
Korhonen, Sanni
Lehtonen, Marko
Sjövall, Sari
Kokki, Merja
author_sort Härkänen, Lasse
collection PubMed
description METHODS: Fifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 µg/h) for five consecutive weeks, starting two weeks prior to the surgery. Simultaneous plasma and cerebrospinal fluid (CSF) samples were collected during spinal anesthesia. RESULTS: Median buprenorphine plasma and CSF concentrations at steady-state were 54 pg/mL (range 8.6 – 167 pg/mL) and 1.6 pg/mL (0.30 – 7.3 pg/mL), respectively. The median CSF/plasma -ratio was 3% (range 0.35 – 16%). Large between-subject variability was observed in the measured buprenorphine concentrations within the study population.
format Online
Article
Text
id pubmed-10663223
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106632232023-10-21 Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing Härkänen, Lasse Hakomäki, Henriikka Huopio, Jukka Kokki, Hannu Korhonen, Sanni Lehtonen, Marko Sjövall, Sari Kokki, Merja Eur J Clin Pharmacol Research METHODS: Fifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 µg/h) for five consecutive weeks, starting two weeks prior to the surgery. Simultaneous plasma and cerebrospinal fluid (CSF) samples were collected during spinal anesthesia. RESULTS: Median buprenorphine plasma and CSF concentrations at steady-state were 54 pg/mL (range 8.6 – 167 pg/mL) and 1.6 pg/mL (0.30 – 7.3 pg/mL), respectively. The median CSF/plasma -ratio was 3% (range 0.35 – 16%). Large between-subject variability was observed in the measured buprenorphine concentrations within the study population. Springer Berlin Heidelberg 2023-10-21 2023 /pmc/articles/PMC10663223/ /pubmed/37864723 http://dx.doi.org/10.1007/s00228-023-03583-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Härkänen, Lasse
Hakomäki, Henriikka
Huopio, Jukka
Kokki, Hannu
Korhonen, Sanni
Lehtonen, Marko
Sjövall, Sari
Kokki, Merja
Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title_full Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title_fullStr Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title_full_unstemmed Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title_short Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
title_sort buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663223/
https://www.ncbi.nlm.nih.gov/pubmed/37864723
http://dx.doi.org/10.1007/s00228-023-03583-4
work_keys_str_mv AT harkanenlasse buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT hakomakihenriikka buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT huopiojukka buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT kokkihannu buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT korhonensanni buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT lehtonenmarko buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT sjovallsari buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing
AT kokkimerja buprenorphineplasmaandcerebrospinalfluidconcentrationsinosteoarthritispatientsduringlowdosetransdermalpatchdosing

Ejemplares similares